

29<sup>th</sup> May 2025

- |   |  |
|---|--|
| <p>(1) BSE Limited<br/>Listing Department,<br/>Phiroze Jeejeebhoy Towers,<br/>Dalal Street,<br/>Mumbai 400 001</p> <p><b>Scrip Code: 500087</b></p> | <p>(2) National Stock Exchange of India Limited<br/>Listing Department<br/>Exchange Plaza, 5<sup>th</sup> floor,<br/>Plot no. C/1, G Block,<br/>Bandra Kurla Complex,<br/>Bandra (East), Mumbai - 400 051</p> <p><b>Scrip Code: CIPLA EQ</b></p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG<br/>Societe Anonyme<br/>35A Boulevard Joseph II,<br/>L-1840 Luxembourg</p>                                |  |

**Sub: Intimation under Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)**

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30 of the Listing Regulations, we hereby notify that Cipla (EU) Limited, UK, a wholly owned subsidiary of the Company has incorporated a new wholly owned subsidiary named ‘CiplaRna GmbH’ in Germany, effective 28<sup>th</sup> May 2025.

The details required to be disclosed under the Listing Regulations read with SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11<sup>th</sup> November 2024 on the captioned subject are enclosed to this letter.

Please take the above information on record.

Yours faithfully,  
**For Cipla Limited**

**Rajendra Chopra**  
**Company Secretary**

Prepared by: Muskan Jain

**Annexure - I**

Details as per SEBI circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11<sup>th</sup> November 2024

Sr. No.	Particulars	Details
a)	Name of the target entity, details in brief such as size, turnover etc.	CiplaRna GmbH (“CiplaRna”) has been incorporated as wholly owned subsidiary (“WOS”) in Germany by Cipla (EU) Limited, UK, WOS of the Company w.e.f. 28 <sup>th</sup> May 2025.
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	CiplaRna is a related party.  None of the promoters / promoter group / group companies have any interest in CiplaRna.  Arm’s length: Not Applicable
c)	Industry to which the entity being acquired belongs	Pharmaceutical Industry
d)	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	CiplaRna has been incorporated with the objective of establishing a laboratory for mRNA-based formulation and drug development support.
e)	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
f)	Indicative time-period for completion of the acquisition	Not Applicable; Cipla (EU) Limited has subscribed 25,000 shares of EUR 1 each at par.
g)	Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration
h)	Cost of acquisition or the price at which the shares are acquired	25,000 shares of EUR 1 each at par.
i)	Percentage of shareholding / control acquired and / or number of shares acquired	100%

j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years' turnover, country in which the acquired entity has presence and any other significant information (in brief)	<b>Brief Background:</b> Refer point (c) and (d) <b>Date of Incorporation:</b> 28 <sup>th</sup> May 2025 <b>Country:</b> Germany <b>Turnover:</b> Not Applicable
----	---	---

**Cipla Ltd.**

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India

P +91 22 41916000 F +91 22 41916120 W [www.cipla.com](http://www.cipla.com) E-mail [contactus@cipla.com](mailto:contactus@cipla.com) Corporate Identity Number L24239MH1935PLC002380